Back to Newsroom

Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”).

Click here to read more